NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) posted its quarterly earnings results on Tuesday, October, 29th. The medical research company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. The medical research company earned $104.70 million during the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The firm's revenue for the quarter was up 51.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.05 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for NeoGenomics.

NeoGenomics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

7 brokers have issued 1-year target prices for NeoGenomics' stock. Their forecasts range from $14.00 to $35.00. On average, they anticipate NeoGenomics' stock price to reach $24.67 in the next twelve months. This suggests that the stock has a possible downside of 25.5%. View Analyst Price Targets for NeoGenomics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

Press coverage about NEO stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeoGenomics earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for NeoGenomics.

NeoGenomics saw a drop in short interest in January. As of January 31st, there was short interest totalling 6,310,000 shares, a drop of 8.8% from the January 15th total of 6,920,000 shares. Based on an average daily trading volume, of 745,100 shares, the short-interest ratio is presently 8.5 days. Approximately 6.4% of the shares of the company are sold short. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Steris (STE), Fisher & Paykel Healthcare (FPH), SYSMEX CORP/ADR (SSMXY), Hologic (HOLX), Cochlear (COH), Insulet (PODD), EXACT Sciences (EXAS), Varian Medical Systems (VAR), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), BioScrip (BIOS), Bausch Health Companies (BHC), Bio-Rad Laboratories (BIO), Universal Health Services (UHS) and Bio-Rad Laboratories (BIO.B).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), Marvell Technology Group (MRVL), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Canopy Growth (CGC), Amarin (AMRN), CVS Health (CVS) and Netflix (NFLX).

NeoGenomics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Kopp Family Office LLC (4.64%), Janus Henderson Group PLC (3.33%), Artisan Partners Limited Partnership (2.81%), State Street Corp (2.65%), Eagle Asset Management Inc. (2.38%) and Granite Investment Partners LLC (1.84%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Marshall Wace LLP, Emerald Advisers LLC, Franklin Resources Inc., Eagle Asset Management Inc., Janus Henderson Group PLC, Falcon Point Capital LLC and Nicholas Investment Partners LP. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was bought by a variety of institutional investors in the last quarter, including Kopp Family Office LLC, Artisan Partners Limited Partnership, Redwood Investments LLC, Driehaus Capital Management LLC, Candriam Luxembourg S.C.A., TCW Group Inc., California Public Employees Retirement System and Bullseye Asset Management LLC. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $33.10.

NeoGenomics has a market capitalization of $3.46 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]